Pricing Log in Create free account

ADARx Pharmaceuticals, Inc. (ADRX) vs Ultragenyx Pharmaceutical Inc. (RARE)

ADARx Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. ADARx Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. are of similar size ($1.7B and $1.7B).

Valuation

Metric ADRX RARE Biotechnology median
P/E — n/m 11.36
P/S — 2.25 9.12
P/B — n/m 2.14
Price to free cash flow — n/m 26.34
EV/EBITDA — n/m 0.62
EV/Sales — 1.89 8.56
Earnings yield — (32.17%) (34.18%)
Free cash flow yield — (27.15%) (23.62%)

Profitability

Metric ADRX RARE Biotechnology median
Gross margin — 82.88% 67.24%
Operating margin — (63.98%) 0.00%
Net margin — (71.72%) 0.00%
Free cash flow margin — (61.20%) 0.00%
Return on equity — 285.46% (50.28%)
Return on assets — (44.05%) (45.89%)
Return on invested capital — 0.00% 0.00%

Growth

Metric ADRX RARE Biotechnology median
Revenue growth (TTM) — 15.78% 6.96%
EPS growth (last fiscal year) — 7.31% 29.86%
Revenue growth, 5-year CAGR — 19.95% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ADRX RARE Biotechnology median
Debt to equity — 0.00 0.00
Current ratio — 1.40 4.72
Net debt to EBITDA — 1.35 1.01

Dividend

Metric ADRX RARE Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric ADRX RARE Biotechnology median
Market cap 1.65b 1.66b 167.45m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack